Medical

Toxicology Screen Results

Buy and sell toxicology screen results data. Drug panels, poison detection, workplace testing — toxicology AI needs diverse real-world screening data.

CSVJSONHL7FHIRXML

No listings currently in the marketplace for Toxicology Screen Results.

Find Me This Data →

Overview

What Is Toxicology Screen Results Data?

Toxicology screen results data comprises comprehensive drug testing records from clinical, workplace, and forensic settings. This includes urine immunoassays, mass spectrometry confirmations, and poison center reports documenting drug exposures, substance detection, and clinical outcomes. The data captures false-positive patterns, demographic characteristics, exposure routes, and toxicological findings across diverse populations and testing methodologies. Healthcare facilities employ multiple testing approaches ranging from rapid point-of-care immunoassays to chromatographic and mass spectrometry-based techniques, each with distinct trade-offs in cost, speed, and accuracy. Toxicology AI systems rely on diverse real-world screening datasets to improve detection algorithms, understand false-positive mechanisms, and validate clinical decision-making across emergency departments, poison control centers, and occupational health programs. This data category spans acute overdoses, chronic substance use patterns, pediatric exposures, and occupational toxicant detection—providing machine learning systems with the ground truth needed to enhance screening accuracy and clinical utility.

Market Data

148,210 cases

Bupropion exposures reported to U.S. poison centers (2011-2021)

Source: PubMed Central

48.1%

Bupropion single-substance exposures

Source: PubMed Central

47.4% (2,878 of 6,073)

Products tested containing measurable heavy metals

Source: PubMed Central

44.7% (63 of 141)

Pediatric cardiac arrest cases without toxicology screening

Source: ScienceDirect

Who Uses This Data

What AI models do with it.do with it.

01

Emergency Medicine & Poison Control

Poison centers and emergency departments use toxicology screening results to track exposure trends, identify emerging substances, and optimize treatment protocols. Analysis of 148,210+ bupropion exposures illustrates how screening data informs clinical decision-making for overdose management.

02

AI-Driven Screening Validation

Machine learning platforms leverage toxicology datasets to reduce false positives in immunoassay screening, distinguish confounding substances, and improve confirmatory testing strategies through pattern recognition.

03

Workplace & Occupational Health

Employers and occupational medicine programs use toxicology screen results to monitor workplace substance use, ensure compliance with safety protocols, and evaluate cost-effective testing methodologies.

04

Clinical Research & Epidemiology

Researchers analyze screening data to track exposure demographics, identify high-risk populations (e.g., 29.1% of bupropion exposures in ages 20-29), and evaluate temporal trends in substance use.

What Can You Earn?

What it's worth.worth.

Individual Screen Results

Varies

Per-result pricing depends on testing methodology (immunoassay vs. mass spectrometry confirmation), sample type, and metadata completeness.

Bulk Toxicology Datasets

Varies

Large institutional datasets with demographic, temporal, and outcome annotations command premium pricing based on sample volume and clinical context.

Annotated Pediatric/Specialized Screens

Varies

Pediatric cardiac arrest screens and rare toxicant detections with complete clinical narratives typically yield higher per-record compensation.

What Buyers Expect

What makes it valuable.valuable.

01

Accurate, Confirmed Results

Immunoassay screening results should be paired with confirmatory mass spectrometry data. False-positive amphetamine screens and other cross-reactivity issues must be documented to support AI model training.

02

Complete Demographic & Clinical Context

Buyers require age, route of exposure (ingestion, inhalation, etc.), time-stamped results, and clinical outcomes. Pediatric cases and unwitnessed exposures carry higher research value due to screening completion challenges.

03

Substance & Metabolite Specificity

Data must clearly distinguish between administered medications and illicit substances. Heavy metal contamination levels, reference standard comparisons, and ppb/ppm quantification add significant value.

04

De-identification & Compliance

All records must be HIPAA-compliant, with personal identifiers removed. Institutional source documentation (poison centers, emergency departments, occupational health programs) strengthens dataset credibility.

Companies Active Here

Who's buying.buying.

Emergency Medicine Networks & Poison Control Centers

Aggregating multi-center toxicology screening data to model exposure trends, validate protocols, and benchmark testing performance across 148,000+ annual poison center reports.

Machine Learning Healthcare Platforms

Training AI models to reduce false positives in immunoassay screening, improve substance differentiation, and optimize confirmatory testing algorithms for clinical use.

Occupational Health & Workplace Testing Providers

Benchmarking cost-effective testing methodologies and validating rapid screening protocols for workplace substance use monitoring and safety compliance.

Clinical Research Institutions & Epidemiologists

Analyzing demographic trends in substance exposures, tracking temporal patterns (e.g., teenage bupropion exposures increasing 15.7% to 18.7%), and identifying high-risk populations.

FAQ

Common questions.questions.

What types of toxicology screens have the highest research value?

Confirmed results with both immunoassay and mass spectrometry data, combined with complete demographic context (age, route of exposure, outcomes), command premium pricing. Pediatric cases and rare substance detections from clinical settings are particularly valuable for AI training.

How common are false positives in toxicology screening?

Immunoassays are prone to false-positive results and require confirmation by mass spectrometry. Large-scale reviews of urine drug screens document cross-reactivity patterns—understanding these error mechanisms is critical for developing accurate AI detection models.

What compliance and privacy issues apply to toxicology data sales?

All toxicology screening results must be de-identified and HIPAA-compliant, with personal identifiers removed. Data should be sourced from institutional settings (hospitals, poison centers, occupational health programs) with documented consent for research use.

Who are the primary buyers of toxicology screening datasets?

Emergency medicine networks, poison control centers, machine learning healthcare platforms, occupational health providers, and clinical researchers are active in this market. They use the data to validate screening protocols, train AI models, and analyze substance exposure epidemiology.

Sell yourtoxicology screen resultsdata.

If your company generates toxicology screen results, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.

Request Valuation